Related Experiment Video
Updated: Jan 15, 2026
06:26
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
689
Taming fatty liver: can taurine combat metabolic dysfunction in MASLD?
Lin Meng1, Fayu Lu2, Bing Zhang3
1First Clinical College, China Medical University, Shenyang, Liaoning Province, 110122, China.
Cell Communication and Signaling : CCS
|October 15, 2025
Summary
Metabolic dysfunction associated with steatotic liver disease (MASLD) is a growing global health issue. This review highlights taurine
Area of Science:
- Hepatology and metabolic research.
Background:
- Metabolic dysfunction associated with steatotic liver disease (MASLD) is the most common chronic liver disease worldwide.
- MASLD involves excessive liver lipid accumulation, potentially progressing to non-alcoholic steatohepatitis (NASH), fibrosis, and hepatocellular carcinoma (HCC).
- Current understanding of MASLD molecular mechanisms is incomplete, with no approved pharmacological treatments.
Purpose of the Study:
- To explore MASLD pathogenesis mechanisms.
- To review early diagnostic strategies for MASLD.
- To investigate the potential of taurine in mitigating MASLD progression through the gut-liver axis.
Main Methods:
- This study is a review of existing literature.
- It synthesizes current research on MASLD.
- It focuses on the role of the gut-liver axis and taurine.
Main Results:
- MASLD pathogenesis mechanisms require further elucidation.
- Early diagnostic tools are under development.
- Taurine shows promise in potentially reducing MASLD progression.
Conclusions:
- Taurine may represent a novel therapeutic strategy for MASLD.
- Further research into taurine's effects could lead to new clinical interventions for MASLD management.
Related Concept Videos
01:24Overview of Lipid Metabolism
4.8K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
4.8K
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
180
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
180
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
211
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
211
01:19Overview of Carbohydrate Metabolism
3.2K
Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
3.2K
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
165
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
165
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
249
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
249